Holen Sie sich die Stockscreener-App
5.85
2.81%
0.16
Handel nachbörslich:
5.84
-0.010
-0.17%
Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten
Vanguard Group Inc's Strategic Acquisition of OnKure Therapeutics Shares - GuruFocus.com
After A Clear Safety Picture, OnKure Prepares For Pivotal PIKture-01 Data On OKI-219 - RTTNews
Jones Trading sets OnKure stock Buy rating, $32 target - MSN
Jones Trading sets OnKure stock Buy rating, $32 target By Investing.com - Investing.com South Africa
Jones Trading Initiates Coverage of OnKure Therapeutics (OKUR) with Buy Recommendation - MSN
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 3.4% – Here’s Why - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $5.66 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $5.66 - Investing.com India
Reneo Pharmaceuticals stock hits 52-week low at $7.64 By Investing.com - Investing.com Australia
Reneo Pharmaceuticals stock hits 52-week low at $7.64 - Investing.com India
OnKure Therapeutics (NASDAQ:OKUR) Trading 4% Higher – Time to Buy? - Defense World
Reneo Pharmaceuticals stock hits 52-week low at $7.91 By Investing.com - Investing.com Nigeria
Reneo Pharmaceuticals stock hits 52-week low at $7.91 - Investing.com India
OKUR Stock Hits 52-Week Low at $10.51 Amid Market Challenges - Investing.com Australia
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 - Markets Insider
OnKure reports positive early trial data for cancer drug OKI-219 - Investing.com India
OnKure Therapeutics Advances Cancer Drug Trials - TipRanks
Form 424B3 OnKure Therapeutics, - StreetInsider.com
SEC Form 424B3 filed by OnKure Therapeutics Inc. - Quantisnow
OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219 - TipRanks
OnKure's OKI-219 Cancer Drug Shows Promising Safety Data, 95% Tumor Marker Reduction in Clinical Trial - StockTitan
Brokers Offer Predictions for OKUR FY2024 Earnings - Defense World
Leerink Partners Initiates Coverage of OnKure Therapeutics (OKUR) with Outperform Recommendation - MSN
OnKure Therapeutics stock has strong potential with Outperform rating from Leerink - Investing.com
OnKure Therapeutics Reports Strategic Merger and Financial Updates - TipRanks
OnKure Announces New Date for Upcoming Investor Call - GlobeNewswire
Head to Head Survey: OnKure Therapeutics (OKUR) vs. Its Rivals - Defense World
OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth - MSN
OnKure Therapeutics (OKUR) vs. The Competition Head-To-Head Analysis - Defense World
OnKure Therapeutics' (OKUR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
OnKure Therapeutics announces accounting firm change - Investing.com India
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
OnKure to Present at the Stifel 2024 Healthcare Conference - GlobeNewswire
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire
vTv Therapeutics Faces License Agreement Termination - Yahoo Finance
VTv, OnKure Terminate Cellular Drug Licensing Agreement - MarketWatch
vTv Therapeutics ends key license agreement with OnKure - Investing.com
vTv Therapeutics ends key license agreement with OnKure By Investing.com - Investing.com UK
OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond (OKUR) - Seeking Alpha
Q3 Earnings Forecast for OKUR Issued By HC Wainwright - MarketBeat
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):